Results 231 to 240 of about 10,658,076 (388)

Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas

open access: yesWorld Psychiatry, 2017
Nancy H. Liu   +28 more
semanticscholar   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

The care transitions intervention: results of a randomized controlled trial.

open access: yesArchives of Internal Medicine, 2006
E. Coleman   +3 more
semanticscholar   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Integration of a WASH Component in the Standard National Protocol for Treatment of Severe Acute Malnutrition in Children Aged 6-59 Months in Northern Senegal-A Costing Study. [PDF]

open access: yesMatern Child Nutr
Wassonguema B   +11 more
europepmc   +1 more source

Adapting Proteostasis for Disease Intervention

open access: yesScience, 2008
W. Balch   +3 more
semanticscholar   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Social work assessment and intervention, 2nd ed.

open access: green, 2011
Steven Walker, Chris Beckett
openalex  

Home - About - Disclaimer - Privacy